PDF(Sci-hub)
Abstract：
Debate continues surrounding the indications for adjuvant and salvage radiotherapy as the published randomized trials have only addressed adjuvant treatment. Salvage radiotherapy has been advocated to limit significant toxicity to patients that would not have benefited from immediate adjuvant radiotherapy. The American Urological Association and American Society for Radiation Oncology guideline released in 2013 has since recommended offering adjuvant therapy to all patients with any adverse features and salvage to those with prostate-specific antigen or local recurrence. The suggested criteria is limited in its application as it potentially subjects patients with few adverse features to adjuvant therapy despite not qualifying as high risk according to established postoperative predictive tools such as the Kattan nomogram. This article reviews the indications for postoperative radiotherapy, limitations of the guideline and alternative prognostication tools for clinicians faced with biochemical or locally recurrent post-prostatectomy prostate cancer.
摘要：
围绕辅助和挽救性放疗的适应症的辩论仍在继续，因为已发表的随机试验仅涉及辅助治疗。已提倡挽救性放射疗法，以限制对不会从立即辅助放射疗法中受益的患者的显着毒性。自2013年发布的美国泌尿外科协会和美国放射肿瘤学会指南以来，建议对所有具有任何不良特征的患者提供辅助治疗，并挽救具有前列腺特异性抗原或局部复发的患者。建议的标准在其应用中受到限制，因为尽管根据已建立的术后预测工具（例如Kattan列线图）不符合高风险，但仍可能使具有很少不良特征的患者接受辅助治疗。本文综述了术后放疗的适应证,对于面临生化或局部复发性前列腺切除术后前列腺癌的临床医生，指南和替代预后工具的局限性。
